Cardiovascular risk factors are independently associated with COVID-19 mortality: a prospective cohort study

Didier Collard, Nick S. Nurmohamed, Yannick Kaiser, Laurens F. Reeskamp, Tom Dormans, Hazra S. Moeniralam, Suat Şimşek, Renée A. Douma, Annet Eerens, Auke C. Reidinga, Paul Elbers, Martijn Beudel, Liffert Vogt, Erik S.g. Stroes, Bert‐Jan H. van den BornmedRxiv 2020 · DOI

Abstract

Recent clinical observations have noted a high prevalence of hypertension and diabetes among patients hospitalized with COVID-19. However, whether these cardiovascular disease (CVD) risk factors independently drive mortality or merely reflect the advanced age of the most vulnerable patients has remained unclear. This study analyzed data from the prospective Dutch COVID-PREDICT cohort (n=1,604) to evaluate the relationship between hypertension, dyslipidemia, diabetes, and clinical outcomes. The findings demonstrate that the accumulation of these risk factors leads to a stepwise increase in 21-day mortality, independent of age and sex.

Introduction

Since the onset of the COVID-19 pandemic, age has been identified as the primary risk factor for severe disease and death. Concurrently, clinicians observed that many severely ill patients presented with comorbidities such as hypertension and diabetes. This raised a critical question for risk stratification: are these cardiovascular risk factors independent drivers of poor outcomes, or are they simply markers of the aging process?

To address this, researchers utilized the COVID-PREDICT initiative to investigate the time-to-event relationship between CVD risk factors and outcomes including mortality and ICU admission. By adjusting for age and sex, the study sought to isolate the specific impact of metabolic and cardiovascular health on the clinical course of COVID-19.

Methodology

The study analyzed a cohort of 1,604 adult patients admitted to eight Dutch hospitals (including two university centers) between February and July 2020. Inclusion required a positive PCR test or high suspicion based on CT imaging.

Surrogate Markers for Risk Factors

Given the challenges of obtaining comprehensive medical histories during a pandemic surge, the researchers used home medication lists as surrogate markers for CVD risk factors:

  • Hypertension: Use of antihypertensive medication.
  • Dyslipidemia: Use of lipid-lowering therapy.
  • Diabetes: Use of antidiabetic medication.

The intensity of these conditions was further proxied by the number of medication classes prescribed (e.g., taking two or more types of glucose-lowering drugs indicated more advanced or difficult-to-manage diabetes).

Statistical Approach

The primary endpoint was mortality within 21 days of admission. Secondary endpoints included ICU admission and ICU-specific mortality. The team employed Kaplan-Meier survival curves and Cox-regression models, adjusting for age and sex, and in secondary analyses, for obesity, smoking, and history of ischemic heart disease.

Results

Of the 1,604 patients (mean age 66; 60.5% male), 19.2% reached the primary endpoint of mortality or discharge for palliative care within 21 days.

The Stepwise Increase in Risk

The presence of multiple risk factors was strongly associated with mortality. After adjusting for age and sex, patients with two or more risk factors faced a significantly higher risk compared to those with none:

  • Cumulative Risk: The presence of ≥2 risk factors was associated with a 52% increase in mortality risk (HR 1.52, 95% CI 1.15–2.02).
  • Medication Intensity: The severity of the underlying condition, as measured by medication burden, also predicted outcomes. Patients taking ≥2 classes of antidiabetics had an HR of 2.09, while those on ≥2 antihypertensives had an HR of 1.46.

The ICU Paradox

Interestingly, while CVD risk factors were potent predictors of mortality, they were not significantly associated with an increased rate of ICU admission. This suggests that the increased mortality observed in patients with multiple comorbidities may occur outside the ICU setting.

Discussion

The findings highlight a "stepwise" progression of risk: as metabolic and cardiovascular burdens accumulate, the body’s resilience against COVID-19 diminishes.

Diabetes as a Primary Driver

Among the factors studied, diabetes (proxied by antidiabetic use) showed the strongest independent association with mortality. This suggests that the specific pathophysiology of diabetes—potentially involving chronic inflammation, endothelial dysfunction, or impaired immune response—may uniquely exacerbate the viral impact of SARS-CoV-2.

Triage and Decision-Making

The lack of association between risk factors and ICU admission (the "ICU Paradox") warrants attention. The authors suggest this may reflect "triage bias" or shared decision-making. Patients with advanced age and multiple comorbidities might have been less likely to be admitted to the ICU in favor of palliative care, leading to higher mortality rates without a corresponding spike in ICU utilization.

Conclusion

This prospective study confirms that hypertension, dyslipidemia, and diabetes are independent predictors of short-term mortality in hospitalized COVID-19 patients. These factors provide prognostic value beyond age and sex alone. While the use of medication as a surrogate for diagnosis is a limitation, the clear stepwise increase in risk underscores the need for aggressive monitoring of patients with multiple metabolic comorbidities. Future research should focus on the biological mechanisms that make these patients particularly vulnerable to the systemic effects of COVID-19.

Summary updated

Abstract

Abstract Objectives Recent reports suggest a high prevalence of hypertension and diabetes in COVID-19 patients, but the role of cardiovascular disease (CVD) risk factors in the clinical course of COVID-19 is unknown. We evaluated the time-to-event relationship between hypertension, dyslipidemia, diabetes, and COVID-19 outcomes. Design We analyzed data from the prospective Dutch COVID-PREDICT cohort, an ongoing prospective study of patients admitted for COVID-19 infection. Setting Patients from 8 participating hospitals, including two university hospitals from the COVID-PREDICT cohort were included. Participants Admitted, adult patients with a positive COVID-19 polymerase chain reaction (PCR) or high suspicion based on CT-imaging of the thorax. Patients were followed for major outcomes during hospitalization. CVD risk factors were established via home medication lists and divided in antihypertensives, lipid lowering therapy, and antidiabetics. Primary and secondary outcomes measures The primary outcome was mortality during the first 21 days following admission, secondary outcomes consisted of ICU-admission and ICU-mortality. Kaplan-Meier and Cox-regression analyses were used to determine the association with CVD risk factors. Results We included 1604 patients with a mean age of 66±15 of whom 60.5% were men. Antihypertensives, lipid lowering therapy, and antidiabetics were used by 45%, 34.7%, and 22.1% of patients. After adjustment for age and sex, the presence of ≥2 risk factors was associated with increased mortality risk (HR 1.52, 95%CI 1.15-2.02), but not with ICU-admission. Moreover, the use of ≥2 antidiabetics and ≥2 antihypertensives was associated with mortality independent of age and sex with HRs of respectively 2.09 (95%CI 1.55-2.80) and 1.46 (95%CI 1.11-1.91). Conclusions The accumulation of hypertension, dyslipidemia and diabetes leads to a stepwise increased risk for short-term mortality in hospitalized COVID-19 patients independent of age and sex. Further studies investigating how these risk factors disproportionately affect COVID-19 patients are warranted. Strengths and limitations of this study While previous data reported a high prevalence of CVD risk factors in COVID-19 patients, this study investigated whether diabetes, dyslipidemia and hypertension predict adverse outcomes. This study is limited by the use of medication as surrogate for cardiovascular risk factors The causality of the investigated risk factors remains to be addressed in future studies.
BibTeX
@misc{collard2020cardiovascular,
  author = {Didier Collard and Nick S. Nurmohamed and Yannick Kaiser and Laurens F. Reeskamp and Tom Dormans and Hazra S. Moeniralam and Suat Şimşek and Renée A. Douma and Annet Eerens and Auke C. Reidinga and Paul Elbers and Martijn Beudel and Liffert Vogt and Erik S.G. Stroes and Bert‐Jan H. van den Born},
  title = {{Cardiovascular risk factors are independently associated with COVID-19 mortality: a prospective cohort study}},
  year = {2020},
  doi = {10.1101/2020.10.01.20205229},
  howpublished = {medRxiv},
}
Figure